Attached files

file filename
EX-10.7 - EXHIBIT 10.7 - OPIANT PHARMACEUTICALS, INC.v476254_ex10-7.htm
EX-32.1 - EXHIBIT 32.1 - OPIANT PHARMACEUTICALS, INC.v476254_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - OPIANT PHARMACEUTICALS, INC.v476254_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - OPIANT PHARMACEUTICALS, INC.v476254_ex31-1.htm
EX-21.1 - EXHIBIT 21.1 - OPIANT PHARMACEUTICALS, INC.v476254_ex21-1.htm
EX-10.52 - EXHIBIT 10.52 - OPIANT PHARMACEUTICALS, INC.v476254_ex10-52.htm
EX-10.9 - EXHIBIT 10.9 - OPIANT PHARMACEUTICALS, INC.v476254_ex10-9.htm
EX-10.6 - EXHIBIT 10.6 - OPIANT PHARMACEUTICALS, INC.v476254_ex10-6.htm
EX-10.5 - EXHIBIT 10.5 - OPIANT PHARMACEUTICALS, INC.v476254_ex10-5.htm
10-K - 10-K - OPIANT PHARMACEUTICALS, INC.v476254_10k.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Opiant Pharmaceuticals, Inc. (the “Company") for the year ended July 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David D. O’Toole, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: October 13, 2017

 

  By: /s/ David D. O’Toole  
  David D. O’Toole  
  Chief Financial Officer